Studies: Pfizer's Prevenar 13 noninferior to Merck's Pneumovax in adults, superior in some groups
10 May 2011
Donna Young
Please Login to read the full article.
10 May 2011
Donna Young
donna.young@informa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: Manufacturing incentives, R&D credit at heart of Obama tax fix
- Prevnar 13 data addition causes sBLA delays in US for unlucky Pfizer
- Prevnar 13 poised for wider paediatric market
- US Capitol Capsule: IOM analysis finds little evidence of vaccine harm, debunks autism link
FEATURES
Other Informa Features
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
